Controlling Nutritional Status (CONUT) Score Is a Prognostic Factor for Patients with Gastric Cancer Treated by Perioperative FLOT

Akagündüz, Baran; Demir, Metin; Atcı, Muhammet Mustafa

doi:10.1007/s12029-021-00664-4

Cited by 8 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure 1 , a total of 138 records were yielded after searching the databases. Through careful title, abstract assessment and full text assessment, 19 studies ( 12 – 18 , 25 – 36 ) with 21 cohorts were finally included in the present study. The basic information and clinical characteristics of the included studies were summarized in Tables 2 , 3 , respectively.…”

Section: Resultsmentioning

confidence: 99%

Clinical significance of the controlling nutritional status (CONUT) score in gastric cancer patients: A meta-analysis of 9,764 participants

et al. 2023

View full text Add to dashboard Cite

BackgroundThe clinical value of the controlling nutritional status (CONUT) score has been widely reported in multiple malignancies. The aim of this study is to investigate the association between the CONUT score and clinical outcomes in patients with gastric cancer.MethodsA comprehensive literature search of electronic databases including PubMed, Embase, and Web of Science was performed up to December 2022. The primary endpoints were survival outcomes and postoperative complications. Subgroup analysis and sensitivity analysis were performed during the pooled analysis.ResultsNineteen studies including 9,764 patients were included. The pooled results indicated that patients in the high CONUT group had a worse overall survival (HR = 1.70 95%CI: 1.54–1.87; P < 0.0001; I2 = 33%) and recurrence-free survival (HR = 1.57; 95%CI: 1.36–1.82; P < 0.0001; I2 = 30%), and a higher risk of complications (OR = 1.96; 95%CI: 1.50–2.57; P < 0.0001; I2 = 69%). In addition, a high CONUT score was significantly associated with larger tumor size, higher percentage of microvascular invasion, later TNM stage and fewer patients receiving adjuvant chemotherapy, but not with tumor differentiation.ConclusionBased on existing evidence, the CONUT score could act as a valuable biomarker to predict clinical outcomes in patients with gastric cancer. Clinicians could use this useful indicator to stratify patients and formulate individual treatment plans.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical significance of the controlling nutritional status (CONUT) score in gastric cancer patients: A meta-analysis of 9,764 participants

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Eastern Cooperative Oncology Group performance status (ECOG PS) regarded as an important prognostic factor for assessing treatment response and outcomes in cancer patients [38,39]. In a study conducted with 161 GC patients who received perioperative chemotherapy, it was reported that the survival time of patients with poor nutritional and performance status was signi cantly shorter than those with good performance [40].…”

Section: Discussionmentioning

confidence: 99%

Malnutrition as a Prognostic Factor in the Survival of Patients With Gastric Cancer

Bıçaklı

Miftari

Almuradova

et al. 2023

Preprint

View full text Add to dashboard Cite

Objective The purpose of this study was to identify the effects of nutritional status and sarcopenia on survival in gastric cancer (GC) patients. Research Methods: This prospective study was conducted with 150 GC patients at the oncology outpatient clinic. Malnutrition and sarcopenia status were determined according to The Patient Generated Subjective Global Assessment (PG-SGA) and anthropometric measurements. Survival analyses were conducted using Kaplan–Meier method and Cox-regression analysis. Results The mean age was 60.1 ± 11.4, and 64% (n = 96) were male, 36% were female (n = 54) patients. Severe malnutrition was observed in 63.3% (n = 95) of patients. In univariate analysis, the mean survival time (ST) for patients with a PG-SGA score < 9 point was 76.3 ± 7.4 month (95% CI:61.7–90.9), for patients with PG-SGA score ≥ 9 was 35.8 ± 4.1 month (95% CI:27.8–43.7) (p < 0.001). The mean ST for patients with and without sarcopenia was 32.0 ± 7.3 month (95% CI:17.7–46.3), 54.1 ± 4.8 month (95% CI:44.7–63.6) respectively (p < 0.05). In multivariate analysis, the risk of death in the patients who didn’t undergo gastrectomy [HR = 1.9 (95% CI:1.2–2.9)], malnourished [HR = 2.3 (95% CI:1.5–3.5)], had metastases [HR = 2.4 (95% Cl:1.4-4.0)] was higher. With the adjustment there was no association between the survival and sarcopenia (p > 0,05). Conclusions Malnutrition was identified as one of the independent risk factors for survival in GC patients, similar to the presence of metastases and the absence of gastrectomy. GC patients should be followed carefully in terms of these issues and nutritional interventions should be made when necessary.

show abstract

“…For example, the utility of the controlling nutritional status score has been demonstrated in gastric and breast cancers. 1,2 Glasgow prognostic score (GPS) and modified GPS are used as prognostic factors for several malignancies, and the C-reactive protein (CRP)/albumin ratio (CAR) is a prognostic factor for hepatocellular carcinoma and nonsmall-cell lung cancer. [3][4][5][6] In hematologic malignancies, GPS and CAR were reported as prognostic factors for follicular lymphoma, peripheral T-cell lymphoma, and diffuse large B-cell lymphomas, and pretreatment CRP was reported as a prognostic factor for diffuse large B-cell lymphoma.…”

Section: Introductionmentioning

confidence: 99%

“…Numerous studies have reported the association of inflammatory and nutritional markers with prognosis of malignant tumors. For example, the utility of the controlling nutritional status score has been demonstrated in gastric and breast cancers 1,2 . Glasgow prognostic score (GPS) and modified GPS are used as prognostic factors for several malignancies, and the C‐reactive protein (CRP)/albumin ratio (CAR) is a prognostic factor for hepatocellular carcinoma and non‐small‐cell lung cancer 3–6 .…”

Section: Introductionmentioning

confidence: 99%

Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study

Sakuma,

Fujisawa,

Tanaka

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

The CFA ratio, calculated using pretreatment C‐reactive protein (CRP), fibrinogen, and albumin levels (CRP × fibrinogen/albumin), was previously reported to be a significant prognostic factor for acute myeloid leukemia (AML). This multicenter retrospective study evaluated the prognostic value of the CFA ratio in 328 adult patients with newly diagnosed AML from April 2000 to March 2018. The median age was 49.5 years (range, 15–75 years), and 60.7% of the population were males. According to the European LeukemiaNet (ELN) risk classification, 67 patients (20.4%) were in the favorable‐risk group, 197 patients (60.1%) in the intermediate‐risk group, and 58 patients (17.7%) in the adverse‐risk group. The median CFA ratio was 1.07 (0–67.69). Based on the calculated cutoff CFA ratio of 1.44, the cohort included 176 and 152 patients with low and high CFA ratios, respectively. At a median follow‐up of 91.2 months, the 7‐year overall survival (OS) and disease‐free survival (DFS) rates were 51.2% and 48.6%, respectively, in the overall cohort. The 7‐year OS rates were 61.7% and 39.0% in the low and high CFA ratio groups, respectively (p < 0.001). The 7‐year DFS rates were 58.1% and 37.0% in the low and high CFA ratio groups, respectively (p = 0.004). In univariate analysis, age ≥50 years, male sex, ELN risk class, and comorbidities were associated with poor OS. Age, ELN risk class, comorbidities, and high CFA ratio were associated with poor OS in multivariate analysis. Subgroup analysis revealed that the CFA ratio was significant in the intermediate and adverse ELN risk classes. These findings indicate the prognostic significance of the CFA ratio in AML.

show abstract

Controlling Nutritional Status (CONUT) Score Is a Prognostic Factor for Patients with Gastric Cancer Treated by Perioperative FLOT

Cited by 8 publications

References 26 publications

Clinical significance of the controlling nutritional status (CONUT) score in gastric cancer patients: A meta-analysis of 9,764 participants

Clinical significance of the controlling nutritional status (CONUT) score in gastric cancer patients: A meta-analysis of 9,764 participants

Malnutrition as a Prognostic Factor in the Survival of Patients With Gastric Cancer

Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study

Contact Info

Product

Resources

About